SEARL to Launch a Foreign Medicine Commercially.

In a notification sent to the PSX on 01/09/2025. The Searle Company Limited (SEARL) announced the commercial launch
of the Denosumab injections.

SEARL has informed that the Company has successfully obtained registration of Denosumab injections 120mg and 60mg (biosimilar drugs) from the Drug Regulatory Authority of Pakistan.

The Company, being the product registration holder in Pakistan, has been granted rights under a License Agreement by Mabwell Pharmaceuticals, China (the manufacturer), to market and sell these biosimilar drugs in Pakistan. Denosumab is a monoclonal antibody and is used for the management of osteoporosis (60mg) and oncology care (120mg).

We are pleased to inform you that the Company is now preparing for the commercial launch of Denosumab injections in Pakistan, marking a significant milestone in expanding its product portfolio.

This development reflects the Company’s commitment to enhancing its product offerings and strengthening its business, thereby improving the quality of its earnings and creating greater value for shareholders.

SEARL shares were last trading at Rs. 112.85 today.

⚠️ This post reflects the author’s personal opinion and is for informational purposes only. It does not constitute financial advice. Investing involves risk and should be done independently. Read full disclaimer →